Document Detail

Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
MedLine Citation:
PMID:  20090319     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Thrombolysis with rt-PA is the only approved pharmacological therapy for acute ischemic stroke presently administrable in a 3-hour window (very recently extended to 4.5 h). After this time, the choice is limited to endovascular treatment and antiplatelet drugs, mainly aspirin (ASA), the efficacy of which in the acute phase of stroke has poorly been evaluated. We compared the efficacy of tirofiban, a GP-IIb/IIIa inhibitor, and ASA, with both drugs being administered within 6 h. METHODS: 150 patients were randomly assigned to treatment with tirofiban or ASA, both given for 3 days in a double-blind regimen. Major inclusion criteria were stroke onset within 6 h and a baseline National Institute of Health Stroke Scale (NIHSS) score of 5-25. Outcome variables were the proportion of patients with a NIHSS score reduction of > or =4 points after 72 h, and the proportion of patients with an mRS score of 0-1 at 3 months. RESULTS: The trial, originally planned to enroll 300 patients, was halted after enrollment of 150 patients at interim analysis due to the lack of a trend difference between the 2 treatment groups. Neurological improvement at 72 h was observed in 56% of the patients in each group. At the 3-month follow-up, minimal or absent disability was seen in 45% of the patients in the tirofiban group and 53% in the ASA group; these differences were not statistically significant. Three-month mortality was the same in both groups (10.6%); the rates of symptomatic intracranial hemorrhage were 1% (tirofiban) and 4% (ASA). CONCLUSION: In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke. However, this needs to be confirmed by further studies.
G Torgano; B Zecca; V Monzani; A Maestroni; P Rossi; M Cazzaniga; D Manganaro; C Boiti; E Zilioli; G Borutti; F Falaschi; C Mandelli
Related Documents :
18241759 - Safety of endovascular treatment of carotid artery stenosis compared with surgical trea...
15557909 - Comparison of angioplasty and stenting with cerebral protection versus endarterectomy f...
24638739 - Influence of alprazolam premedication on the occurrence of postoperative obstructive ap...
23106799 - The impact of body mass index on surgical outcomes of robotic partial nephrectomy.
8869049 - Cost-effectiveness of carotid endarterectomy.
20728219 - Early adc changes in motor structures predict outcome of acute stroke better than lesio...
17369999 - The safety and efficacy of a mixture of honey, olive oil, and beeswax for the managemen...
21437759 - Role of intravitreal bevacizumab in adult onset coats' disease.
21998049 - Improved prediction of poor outcome after thrombolysis using conservative definitions o...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2010-01-15
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  29     ISSN:  1421-9786     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-12     Completed Date:  2010-04-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  275-81     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Department of Emergency Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Aspirin / administration & dosage*,  adverse effects
Brain Ischemia / complications,  drug therapy*,  mortality,  physiopathology
Chi-Square Distribution
Disability Evaluation
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Early Termination of Clinical Trials
Fibrinolytic Agents / administration & dosage*,  adverse effects
Hospital Mortality
Intracranial Hemorrhages / etiology
Middle Aged
Platelet Aggregation Inhibitors / administration & dosage*,  adverse effects
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Recovery of Function
Stroke / drug therapy*,  etiology,  mortality,  physiopathology
Time Factors
Treatment Outcome
Tyrosine / administration & dosage,  adverse effects,  analogs & derivatives*
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 50-78-2/Aspirin; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk Factors for Aneurysmal Subarachnoid Hemorrhage in an Indian Population.
Next Document:  Filter-protected versus unprotected carotid artery stenting: a randomised trial.